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higher (p < 0.01), respectively, in the C/T group (complete 
ratio: 75.0 %, duration: 24.8 ± 5.8 days) than in the con-
trols (complete ratio: 35.5 %, duration: 20.0 ± 7.7 days).
Conclusions The oral administration of cystine and thean-
ine attenuated the AEs of S-1 adjuvant chemotherapy and 
increased the S-1 completion rate, suggesting that cystine 
and theanine is a useful supportive care for chemotherapy.
Keywords Adverse events · Chemotherapy · Cystine/
theanine · S-1 · Supportive care
Introduction
Adherence to the dosing schedule is important for the 
effectiveness of anticancer chemotherapy and affects thera-
peutic outcomes [1]. To improve adherence, measures that 
reduce adverse events (AEs) have been considered in the 
area of dosage form design, and the administration method 
has been modified. Drugs that suppress various symptoms 
have also been developed and used as supportive thera-
pies to prevent AEs. Two examples of supportive therapies 
include antiemetics, which mitigate nausea, and granulo-
cyte colony-stimulating factor (G-CSF), which treats neu-
tropenia [2–4]. However, AEs are still difficult to control, 
and further development of supportive therapies is needed.
Cystine and theanine is a supplement that contains 
700 mg cystine and 280 mg theanine; it is available in Japan 
and the United States. Cystine consists of two molecules of 
cysteine, which is a sulfur-containing amino acid, that are 
connected by a disulfide bond, and it is reduced and con-
verted to cysteine in the cell. Theanine breaks down into 
glutamic acid and ethylamine after it is absorbed. In the 
cell, cysteine and glutamic acid are synthesized with gly-
cine to form the tripeptide glutathione (GSH) [5]. GSH is 
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reportedly the most potent antioxidant in the body, and its 
levels have been shown to decrease after exercise and sur-
gery [6, 7]. The need for GSH is thought to increase under 
these conditions. We previously described that the intake of 
cystine and theanine for 10 days during the perioperative 
period led to the early resolution of high postoperative levels 
of interleukin (IL)-6 and C-reactive protein (CRP) and early 
recovery from changes in neutrophil and lymphocyte counts 
[8]. Cystine and theanine has also been shown to produce 
similar effects in mouse digestive tract surgery models and 
to prevent decreases in intestinal GSH; these effects were 
considered to be partly explained by the supply of GSH [9].
Justino et al. showed that the GSH concentrations in 
the epithelial cells of the gastrointestinal mucosa in mice 
decreased after the administration of 5-FU; they also found 
that administering the intestinal bacterial species Saccharo-
myces boulardii prevented the decrease in GSH and allevi-
ated diarrhea, an AE associated with the administration of 
5-FU [10].
Preliminary studies using cystine and theanine have 
shown that this treatment reduced the severity of stomati-
tis caused by various chemotherapies [11], suggesting that 
cystine and theanine is a promising supportive therapy. 
Therefore, we performed a prospective randomized trial in 
patients undergoing surgery for either colon cancer or gas-
tric cancer with postoperative S-1 adjuvant chemotherapy 
to determine the preventive effects of cystine and theanine 
against AEs caused by chemotherapy and to evaluate the 
usefulness of cystine and theanine as a supportive therapy.
Patients and methods
Patients
This study was approved by the Institutional Review Board 
of Sendai City Medical Center (approval number: 2012-
0010), and consent was obtained from each patient after the 
study was sufficiently explained. The study was performed 
in accordance with the Declaration of Helsinki. The subjects 
comprised patients who underwent R0 surgery for either 
colon or gastric cancer at the surgery department of the Sen-
dai City Medical Center and who were expected to receive 
postoperative S-1 adjuvant chemotherapy for 4 weeks with 
a 2-week drug-free interval. Patients were enrolled in the 
study if they were in PS0 or PS1, were 20 years of age or 
above, submitted written consent, and fulfilled the follow-
ing criteria on their pre-registration laboratory tests: white 
blood cell (WBC) count >3,000/mm3, neutrophil count 
>1,500/mm3, platelet count >100,000/mm3, hemoglobin 
level >9.0 g/dl, total bilirubin level <2.0 mg/dl, aspartate 
aminotransferase (AST) level <100 IU, alanine aminotrans-
ferase (ALT) level <100 IU, and estimated glomerular 
filtration rate (eGFR) >60 ml/min. The patient registration 
period lasted from July 2012 to June 2014, and the intended 
number of enrolled subjects was 70.
Study design and data collection
The study design was a prospective randomized trial, and 
the subjects were allocated using the envelope method. The 
administration of S-1 (Taiho Pharmaceutical, Tokyo, Japan) 
was scheduled to be initiated within 6 weeks after surgery. 
The subjects in the C/T group were orally administered 
an amino acid supplement, which contained 700 mg cys-
tine and 280 mg theanine (total weight, 1.7 g; Ajinomoto, 
Tokyo, Japan), once a day starting 1 week before and end-
ing at the same time as the administration of S-1 (a total 
of 35 days) (Fig. 1). The control group received S-1 with-
out cystine and theanine. The subjects in both groups were 
examined at the outpatient clinic immediately before start-
ing S-1 chemotherapy. They underwent blood sampling, 
and it was confirmed that they fulfilled the inclusion cri-
teria. The subjects visited the hospital 14 days after start-
ing S-1 chemotherapy and at the end of the first treatment 
course (28 days after starting S-1 chemotherapy); during 
the visits, they underwent blood sampling and answered 
questions about AEs. The subjects were observed until the 
end of the first treatment course. A physician in charge of 
the outpatient clinic graded the AEs according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE) 
version 4.0. If AEs that were of a grade 2 severity or more 
severe occurred during the chemotherapy, the administra-
tion of S-1 was suspended or discontinued, and the period 
in which S-1 was administered at the prescribed dose (i.e., 
not including the period when the dose was reduced) was 
recorded. Consultations regarding AEs were given by tel-
ephone and during hospital visits, and the administration 
of S-1 was immediately discontinued if the AE was judged 
to be of a grade 2 severity or more severe. The evaluation 
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Fig. 1  Administration schedules of S-1 and cystine and theanine 
after R0 surgery
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items included the incidence of AEs, which was determined 
through blood tests and medical interviews, and the com-
pletion rate of the first course of chemotherapy at the pre-
scribed dose.
Statistical analyses
The hypothesis was that the completion rate of the first 
course of chemotherapy would be increased from 45 % 
(less than half) to 80 % by administration of cystine and 
theanine. It was calculated that 66 samples would be 
required. Expecting the loss of several samples, 70 samples 
were included in this study.
All data were expressed as a percentage or the 
mean ± standard deviation (SD). The incidence of AEs 
and completion rate of chemotherapy were evaluated using 
Fisher’s exact test. The number of days that the prescribed 
dose of S-1 was administered in each group was compared 
using the t test. All statistical procedures were performed 
at a significance level of p < 0.05 using the Prism software 
package (GraphPad Software, La Jolla, CA, USA).
Results
Of the 70 subjects who participated, 35 subjects were allo-
cated to each group. Four subjects in the control group were 
excluded (1 had difficulty visiting the hospital because 
of low back pain, 2 were underdosed with S-1, and 1 was 
administered cystine and theanine), and 3 in the C/T group 
were excluded (1 developed ileus, 1 could not be adminis-
tered S-1, and 1 was not administered cystine and thean-
ine). Thus, 31 subjects in the control group and 32 subjects 
in the C/T group were evaluated (Fig. 2).
The subjects in the control and C/T groups had the fol-
lowing characteristics: their ages were 63.5 ± 8.9 and 
63.2 ± 8.5 years, their male:female ratios were 17:14 and 
21:11, and their diagnoses were colon cancer (n = 24 and 
n = 22) and gastric cancer (n = 7 and n = 9), respectively; 
1 patient in the C/T group had gastric cancer and colon 
cancer (Table 1).
Operative procedures in each group are shown 
in Table 2. Open or laparoscopic procedure was not 
distinguished.
The following incidences for AEs (any grades) were 
observed in the control and C/T groups, respectively: 
16.1 % and 9.4 % for neutropenia, 29.0 % and 18.8 % for 
stomatitis, 38.7 % and 18.8 % for appetite loss, 16.1 % and 
18.8 % for nausea, 41.9 % and 9.4 % for diarrhea, 22.6 % 
and 9.4 % for fatigue, 32.3 % and 25.0 % for pigmentation, 
6.5 % and 0 % for exanthema, 9.7 % and 0 % for fever (not 
accompanied by neutropenia), 9.7 % and 0 % for abdomi-
nal pain, and 3.2 % and 0 % for vertigo. The incidences for 
Fig. 2  Thirty-five subjects each 
were randomly allocated to the 
control and C/T groups. After 
exclusion of 4 control group 
subjects and 3 C/T group sub-
jects, the data from 31 and 32 









C/T administered: 1 case
no visit to the hospital: 1 case 
TS-1 insufficient dose: 2 cases
enrolled: 70 cases
excluded
bowel obstrucon: 1 case
chemotherapy not started: 1 case
C/T not administered: 1 case
C/T : cysne and theanine
Table 1  Characteristics of the subjects in the control and C/T groups
Age was expressed as mean ± SD and compared using the t test. 
Numbers of subjects were compared using percentage. p values were 
calculated using Fisher’s exact test
C/T cystine and theanine
Control C/T p value
Age (years) 63.5 ± 8.9 63.2 ± 8.5 0.917
Sex, male:female (cases) 17:14 21:11 0.556
Colon cancer (cases) 24 22 0.517
Gastric cancer (cases) 7 9
Gastric/colon cancer (cases) 0 1
Total (cases) 31 32
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all AEs, except nausea, were lower in the C/T group than 
in the control group, and a significant difference (p < 0.01) 
was observed in the incidence of diarrhea (Table 3). The 
following incidences for AEs that were of a grade 2 or 
more severity (at which point S-1 administration was sus-
pended or discontinued) were observed in the control and 
the C/T groups, respectively: 16.1 % and 9.4 % for neutro-
penia, 12.9 % and 3.1 % for stomatitis, 19.4 % and 6.3 % 
for appetite loss, 9.7 % and 3.1 % for nausea, 25.8 % and 
3.1 % for diarrhea, 12.9 % and 0 % for fatigue, and 0 % 
and 0 % for pigmentation. The incidences for all these 
AEs were lower in the CT group than in the control group, 
and a significant difference (p < 0.05) was observed in the 
incidence of diarrhea. Exanthema (3.2 %), fever (9.7 %), 
abdominal pain (9.7 %), and vertigo (3.2 %) were noted in 
only the control group (Table 3). With regard to operative 
procedure, incidences of all AEs, except neutropenia and 
appetite loss in gastric cancer patients, were lower in the 
C/T group than in the control group in both colon cancer 
and gastric cancer patients. The incidence of appetite loss 
and diarrhea of any grade was significantly lower (p < 0.05 
and p < 0.01, respectively) in the C/T group than in the 
control group in colon cancer patients.
The percent of subjects who were able to complete the 
first course of chemotherapy at the prescribed dose was 
significantly higher (p < 0.01) in the C/T group (75.0 %) 
than in the the control group (35.5 %) (Table 4). Accord-
ing to sub-analyses, completion rate was significantly 
higher (p < 0.01) in C/T group (90.9 %) than control group 
(41.7 %) in colon cancer patients, and higher, but not sig-
nificant, in C/T group (44.4 %) than control group (14.3 %) 
in gastric cancer patients (Table 4).
The duration of the administration period in which S-1 could 
be administered at the prescribed dose without suspension or 
discontinuation during the first treatment course (scheduled to 
be 28 days) was significantly longer (p < 0.01) in the C/T group 
Table 2  Operative procedures 
in the control and C/T groups
C/T cystine and theanine
Control (cases) C/T (cases) Total (cases)
Colon cancer Rt. colectomy 5 8 13
Sigmoid colectomy 8 5 13
Resection of rectum 6 6 12
Miles’ operation 5 2 7
Partial resection 0 1 1
Gastric cancer Distal gastrectomy 5 3 8
Total gastrectomy 2 6 8
Gastric/colon cancer Distal gastrectomy + rt. colectomy 0 1 1
Total (cases) 31 32 63
Table 3  Incidence of adverse events (AEs) during the first course (28 days) of S-1 therapy
AEs were evaluated using the CTCAE (ver. 4.0)
C/T cystine and theanine
* p < 0.05; ** p < 0.01 vs. control
Group Colon cancer Gastric cancer Total
Control (n = 24) C/T (n = 22) Control (n = 7) C/T (n = 9) Control (n = 31) C/T (n = 32)
Adverse event (AE) (grade) Any (G ≥ 2) Any (G ≥ 2) Any (G ≥ 2) Any (G ≥ 2) Any (G ≥ 2) Any (G ≥ 2)
Neutropenia % 16.7 (16.7) 0 (0) 14.2 (14.2) 33.3 (33.3) 16.1 (16.1) 9.4 (9.4)
Stomatitis 29.2 (8.3) 13.6 (0) 28.6 (28.6) 22.0 (0) 29.0 (12.9) 18.8 (3.1)
Appetite loss 41.7 (20.8) 9.1* (0) 28.6 (14.2) 44.4 (22.2) 38.7 (19.4) 18.8 (6.3)
Nausea 16.7 (12.5) 18.2 (4.5) 14.2 (0) 22.2 (0) 16.1 (9.7) 18.8 (3.1)
Diarrhea 41.7 (25.0) 4.5** (4.5) 42.9 (28.6) 11.1 (0) 41.9 (25.8) 9.4** (3.1*)
Fatigue 16.7 (12.5) 9.1 (0) 42.9 (14.2) 11.1 (0) 22.6 (12.9) 9.4 (0)
Pigmentation 25.0 (0) 22.7 (0) 57.1 (0) 22.2 (0) 32.3 (0) 25.0 (0)
Exantheme 8.3 (4.2) 0 (0) 0 (0) 0 (0) 6.5 (3.2) 0 (0)
Fever 4.2 (4.2) 0 (0) 28.6 (28.6) 0 (0) 9.7 (9.7) 0 (0)
Abdominal pain 8.3 (8.3) 0 (0) 14.3 (14.3) 0 (0) 9.7 (9.7) 0 (0)
Vertigo 4.2 (4.2) 0 (0) 14.3 (14.3) 0 (0) 3.2 (3.2) 0 (0)
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(24.8 ± 5.8 days) than in the control group (20.0 ± 7.7 days). 
According to sub-analyses, the duration was significantly longer 
(p < 0.01) in the C/T group (26.8 ± 3.8 days) than in the control 
group (21.0 ± 7.4 days) in colon cancer patients, and longer, but 
not significant, in the C/T group (21.1 ± 6.8 days) than in the con-
trol group (16.3 ± 8.0 days) in gastric cancer patients (Table 4).
Discussion
The ACTS-GC study reported that the use of S-1 adju-
vant chemotherapy for treating stage II/III gastric cancer 
increased the 5-year survival rate after surgery alone from 
61.7 % to 71.7 % and improved the hazard risk by 32 % 
[12]. A study in Japan that assessed the regimen of orally 
administering uracil, tegafur, and leucovorin (UFT/LV) as 
an adjuvant chemotherapy after colon cancer surgery found 
that it was not inferior to intravenous 5-FU and levofolinate 
(5-Fu/LV) therapy [13]. UFT/LV is recommended in the 
guidelines; however, the ACTS-CC study demonstrated that 
S-1 is not inferior to UFT/LV [14]. The results of this study 
demonstrated that S-1 adjuvant chemotherapy was effective 
following surgery for gastric or colon cancer.
AEs associated with the administration of S-1 have been 
shown to affect the duration of the administration period; S-1 
administered was continued for 12 months with suspensions 
and dose reductions in 65.8 % (340/517) of the patients after 
gastrectomy in the ACTS-GC study [12] and for 6 months in 
76.5 % of the patients after large bowel resection in the ACTS-
CC study [14]. As dose reductions were necessary because 
of the occurrence of AEs in 46.5 % (158 patients) of the 340 
patients who completed the therapy in the ACTS-GC study, the 
percent of patients who completed the therapy without dose 
reductions was 35.2 % (182/517 patients) [12]. In a study by 
Maekawa et al., S-1 was administered for 12 months in 65 % of 
the 40 patients after gastrectomy, and only 23 % of the patients 
did not require a change in the administration schedule or a 
reduction in dose [15]. According to sub-analyses of the ACTS-
GC study results, the outcomes were more favorable among the 
patients who could continue receiving treatment for 12 months 
and the patients who received 70 % or more of the planned 
dose [16]. Therefore, how well AEs can be controlled and how 
much of the scheduled dose can be administered within the 
scheduled treatment period are considered to markedly affect 
the therapeutic outcomes of S-1 adjuvant chemotherapy.
In the present clinical trial, cystine and theanine was shown 
to alleviate the AEs associated with the use of S-1. Moreo-
ver, during the first course of S-1 therapy, cystine and thean-
ine significantly increased the number of days on which S-1 
could be administered and significantly improved the com-
pletion rate of the therapy at the prescribed dose from 35.5 % 
to 75.0 %. Especially, the completion rate of colon cancer 
patients improved from 41.7 % to 90.9 %. The findings also 
suggest that cystine and theanine alleviates all AEs, in contrast 
to drugs such as antiemetics, that target particular symptoms. 
No study has yet demonstrated improvements in the comple-
tion rate of anticancer regimens through the use of particular 
supportive therapies. With respect to the specific symptoms, 
significant suppression was observed only for diarrhea; how-
ever, the effects on the other symptoms may also be significant 
in large-scale studies. The AEs associated with S-1 most fre-
quently occur during the first few treatment courses. If cystine 
and theanine can improve the completion rate of the first treat-
ment course, its suppressive effects on AEs may be sustained 
in subsequent courses in patients who continue to take it. In 
a previous study, we were able to administer the S-1 regimen 
as scheduled without AEs by the continuous administration of 
cystine and theanine in a small number of patients.
With respect to the dose, the final dosage form of the 
cystine and theanine amino acid supplement, which con-
tained 700 mg cystine and 280 mg theanine, weighed 1.7 g, 
and it was readily ingested even by patients with gastroin-
testinal symptoms, which is a major advantage. The find-
ings of all the clinical trials to date are based on the com-
bination of 700 mg cystine and 280 mg theanine; future 
studies should evaluate the optimal dose. In an experiment 
using mice, its effects were not intensified at higher doses, 
suggesting that there is an optimal dose [9, 17].
Although the action mechanism of cystine and theanine has 
not yet been elucidated in detail, it likely involves an increase 
Table 4  Completion rate and the duration of the administration period in which S-1 should be administered at the prescribed dose without sus-
pension or discontinuation during first treatment course (28 days)
Duration was expressed as mean ± SD and compared using the t test
C/T cystine and theanine
** p < 0.01 vs. control
Group Colon cancer Gastric cancer Total
Control C/T Control C/T Control C/T
Completion rate of first course of treatment (cases) 10/24 20/22 1/7 4/9 11/31 24/32
Percent (%) 41.7 90.9** 14.3 44.4 35.5 75.0**
Duration (days) 21.0 ± 7.4 26.8 ± 3.8** 16.3 ± 8.0 21.1 ± 6.8 20.0 ± 7.7 24.8 ± 5.8**
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in the cellular concentration of GSH in the organs that are 
involved in the AEs which occur. Cystine and theanine pro-
vides cysteine and glutamic acid to cells, and in combination 
with glycine, they increase intracellular GSH concentrations. 
The use of an anticancer agent is expected to increase oxidative 
stress in cells and to reduce the concentration of GSH, which is 
a potent antioxidant. Because the administration of cystine and 
theanine for 5 days before laparotomy suppressed decreases in 
GSH in the small bowel mucosa and Peyer’s patches of mice 
[9], this may be the mechanism responsible for alleviation of 
the AEs caused by anticancer chemotherapy. A previous study 
involving 14 patients who had colorectal cancer and underwent 
adjuvant chemotherapy with 5-FU and oxaliplatin reported that 
the incidence of sensory neuropathy was significantly lower in 
5 patients who were orally administered N-acetylcysteine, a 
GSH precursor, at 1200 mg than in the 9 patients who were 
not administered the supplement [18]. Another study found 
that among 52 patients who had colorectal cancer and under-
went oxaliplatin-based chemotherapy, a significantly stronger 
neuroprotective effect was observed in the group that received 
intravenous GSH at 1500 mg/m2 before the administration of 
oxaliplatin [19]. The regimens evaluated in these clinical stud-
ies also aimed to alleviate the AEs caused by chemotherapy by 
increasing the GSH concentration in normal cells.
In conclusion, the intake of the amino acids cystine and 
theanine at 700 and 280 mg, respectively, alleviated the AEs 
caused by the anticancer drug S-1, reduced the frequency of 
therapy suspension or discontinuation caused by AEs, and 
improved the completion rate of the first course of therapy.
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